Answers are grounded in this paper and cite their sources.
In this month's issue, we include three exciting editor's choice studies. The first, by da Silva et al.,1 discusses how hypoallergenic derivatives of Blo t21, a storage and house dust mite, may possess immunomodulatory properties and may serve as a candidate for a safer allergen immunotherapy. Conventional allergen immunotherapy using crude allergen extracts can be effective in treating allergies,2, 3 however, there are also some challenges. Crude allergen extracts can contain various allergenic proteins, and if administered to a patient, they may cause mild to extremely severe allergic reactions. The composition, potency, and quality of crude extracts can vary widely, which makes it difficult to establish standardized dosages for each patient based on their individual needs. The lack of consistency in treatment may also have a negative impact on the outcome of treatment. Patient safety and clinical efficacy can both be affected by variable composition. The recombinant allergens Blo t 5 and Blo t 21 as well as their hybrid derivatives (BTH1 and BTH2) were expressed and purified to produce these hybrid allergens. ELISA was used to test the IgE binding capacity of sera obtained from Brazilian, Colombian, and Ecuadorian patients. In a murine model of allergic airway inflammation, BTH2 was evaluated for its ability to ameliorate allergic airway inflammation induced by Blomia tropicalis extract. rBlot 5 and rBlot 21 have been identified as the most important allergens in Latin American patients, and BTH2 has the lowest level of IgE binding capacity. In vitro stimulation of human cells induced greater levels of IL-10 and IFN-γ and reduced the secretion of Th2 cytokines. As evidenced by histopathological and humoral biomarkers of allergic airway inflammation in B. tropicalis-challenged A/J mice, following BTH2 treatment, allergic airway inflammation was significantly reduced. Th2 cytokines were decreased, eosinophilic infiltration was reduced, eosinophil peroxidase activity was decreased, IgG blocking antibodies were increased, and goblet cells produced much less mucus. Overall BTH2 represents a promising candidate when it comes to the treatment of B. tropicalis allergy due to its hypoallergenic, immunoregulatory, and therapeutic properties. The efficacy and safety of BTH2 as a potential asthma vaccine will need to be investigated further in murine and human in vitro models of chronic asthma to further understand whether it is effective and safe to use. This issue's second editor's choice article evaluates the efficacy of intralymphatic immunotherapy with birch and grass pollen. Intralymphatic immunotherapy (ILIT) is a highly specialized form of allergen immunotherapy in which allergens are injected directly into lymph nodes in order to trigger an immunological response. As a result of targeting the lymph nodes, one of the immune system's responses can be modulated more effectively, possibly resulting in a faster and longer-lasting relief from allergies by modulating the immune system's response.4, 5 A study by Ahlbeck et al.6 evaluated the clinical effectiveness of ILIT in 37 patients with seasonal allergies to birch pollen and grass pollen. In a randomized, controlled study, patients with seasonal allergies to birch and grass pollen were randomized to either intermittent intralymphatic (ILIT) or placebo injections. Prior to and after treatment, daily combined symptom medical scores and rhinoconjunctivitis total symptom scores were recorded. Symptoms, medication, and quality of life scores related to rhinoconjunctivitis were assessed annually after treatment began. Daily combined symptom medical scores did not differ between groups during the first year. After 2 years of ILIT, the actively treated group reported significantly fewer symptoms, lower medication use, and improved quality of life. The authors concluded that ILIT with grass pollen and birch pollen extracts was safe and accompanied by immunological changes. Further studies are required before the clinical efficacy of the treatment can be confirmed or refuted (Figure 1). The third article discusses associations between the gut microbiome among dog-exposed infants and early immune development.7, 8 Early childhood dog exposure has been associated with reduced allergies and asthma in some studies. One potential route to explain such an association is via intestinal microbes. Changes in the gut microbiome among dog-exposed infants may potentially impact early immune development. Panzer et al.9 assessed whether infants born into households with indoor dogs have altered gut microbiome development. Pregnant women living with dogs or without pets in southeast Michigan were recruited. Infant stool samples were collected 1 week to 18 months after birth, and microbiome was assessed using 16S ribosomal sequencing. Sequencing was also undertaken on a limited number of perinatal maternal swabs. To assess stool microbial community trajectories for infants from dog-keeping versus pet-free homes, mixed effect adjusted models were used. Infants born vaginally had gut microbiota similar to mothers as age-related accumulation of bacterial species occurred. A major increase in microbial diversity was observed between 3 and 18 months in stool samples from dogs-exposed infants. Statistically significant associations between dog exposure and β-diversity outcomes were only seen in formula-fed children. Dog exposure was associated with the enrichment of Fusobacterium, Collinsella, Ruminococcus, Clostridaceae and Lachnospiraceae. Further work is needed to establish whether there is a link between these changes in the infant gut microbiome and allergic disorders (Figure 2).
No takes yet. Share an insight, caveat, or question.
Shamji et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: